Inventage Lab

Inventage Lab Asset Growth

The Year-over-Year Total Asset Growth of Inventage Lab (389470.KQ) as of Nov 5, 2026 is 53.13 %. In the previous year, Year-over-Year Total Asset Growth was 59.91 % — a change of -11.32% (lower).

Asset Growth

53.13 %

YoY

-11.32%

Last updated:

Year-over-Year Total Asset Growth of Inventage Lab is 2025 53.13 % . Year-over-Year Total Asset Growth of Inventage Lab was 2024 59.91 % . It decreases by -11.32% lower compared to the previous year.

The Inventage Lab Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2020
79.30 KRW
Jan 1, 2021
42.02 KRW
Jan 1, 2022
9.89 KRW
Jan 1, 2023
29.60 KRW
Jan 1, 2024
59.91 KRW
Jan 1, 2025
53.13 KRW
The Inventage Lab Asset Growth history
YEARAsset GrowthYoY
53.13 %-11.32%
59.91 %+102.39%
29.60 %+199.32%
9.89 %-76.47%
42.02 %-47.00%
79.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Year-over-Year Total Asset Growth of Inventage Lab is 53.13 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Inventage Lab

All Key Metrics — Inventage Lab